It has been reported that the overexpression of BCL-2 antiapoptotic proteins increases resistance in ovarian cancer cells to cisplatin, paclitaxel, and other chemotherapeutic agents, both in vitro and in vivo [82]. This evidence concerns the gene BCL2 and ovarian carcinoma.